Company news

Paradigm Biopharmaceuticals Ltd. news in 2024

Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2024, newest first.

View company

PAR Capital Raising Presentation

December 8, 2024

Successful Completion of $16M Placement for Phase 3

December 8, 2024

Trading Halt

December 4, 2024

Paradigm to Proceed with Phase 3 Knee OA Trial

November 27, 2024

Response to ASX Price Query

November 25, 2024

2024 Chairman Address and AGM Presentation

November 18, 2024

Phase 3 Protocol Submission to US FDA

October 30, 2024

Paradigm Investor Update

October 20, 2024

PAR receives positive response from US FDA for phase 3

September 17, 2024

Appendix 4E and 2024 Annual Report

August 30, 2024

Type D Response Submitted and Received by the US FDA

April 18, 2024

Half Yearly Report and Accounts

February 28, 2024

Primary Endpoint Achieved in Phase 2 MPS VI Trial

February 8, 2024

Paradigm Receives $7.36m R&D Tax Incentive Refund

February 6, 2024

Decks in 2024